US stock futures steady after Wall St gains on rate cut bets; PPI inflation on tap
ANN ARBOR, MI—Jordan Scott, the Chief Financial Officer of Zomedica Corp. (NYSEAMERICAN:ZOM), has purchased 300,000 shares of the company’s common stock. This transaction, which took place on March 17, 2025, was disclosed in a recent SEC filing. The shares were acquired at a price of $0.062 each, amounting to a total investment of $18,600. Following this acquisition, Scott holds 300,000 shares directly. According to InvestingPro data, the stock is currently trading in oversold territory, with the company maintaining a strong balance sheet featuring more cash than debt. Zomedica, a veterinary health company, continues to attract attention from investors and insiders alike. The company’s financial health score is rated as "FAIR" by InvestingPro, which has identified 13 additional key investment factors for this stock. Subscribers can access the comprehensive Pro Research Report, available for over 1,400 US equities, to gain deeper insights into Zomedica’s valuation and growth prospects.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, which signifies an 8% increase compared to the previous year. Despite recording a net loss of $7.2 million, the company maintained strong gross margins and a robust cash position with $71.4 million in liquidity. Zomedica’s full-year revenue for 2024 reached a record $27.3 million, supported by growth in its therapeutic devices and diagnostics segments. The company’s stock experienced a significant increase following the earnings announcement, reflecting positive investor sentiment. Additionally, Zomedica has been focusing on expanding its presence in the equine and international markets as part of its growth strategy. The company is also exploring options to enhance its stock valuation and plans to engage investors through monthly webinars. While Zomedica was recently delisted from the NYSE American Exchange, it has transitioned to the OTCQB market, allowing continued trading of its shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.